Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib, Panitumumab and FOLFIRI in KRAS p.G12C Mutated Metastatic Colorectal Cancer
NCT06252649Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Jul 2024
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, open-label trial of sotorasib in colorectal cancer (CRC) (2 arms), sponsored by Amgen. Primary endpoint: Progression-Free Survival. Started Jul 2024; status: recruiting.
02
Drugs
sotorasib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06252649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252649.